One of Hyloris’ goals is to bring new drugs to the market to meet unmet needs
in rare and orphan disease fields.


About us

Hyloris Pharmaceuticals is focused on 505(b)(2) (new drug application) in rare and orphan diseases, high quality Ready-To-Use and Pre-Filled-Syringe products for the U.S. and European markets.

More about us



Our portfolio covers a wide range of therapeutic indications. We have 9 products in our pipeline. We are constantly reviewing and evaluating upcoming projects to enhance its value.

More about our portfolio


Our Team

Our Team has a significant industry experience, each of us with a background of 20-28 years in business development, operations, product development, clinical and regulatory focus areas. 

More about our team


Pipeline last updated 28th January 2019 


Phase 1 Phase 2 Phase 3 Phase 4 Commercial
Sotalol IV (commercialized)
Arrhythmia disorders
P-004 Project (NDA)
Inherited bleeding disorders
P-002 Project (NDA)
Pain management
P-006 Project (NDA)
Oral mucositis
Podofilox Project (generics)
Vaginal warts
Dinoprostone Project (generics)
Women’s health

Comments are closed